Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-05T09:23:41.076Z Has data issue: false hasContentIssue false
  • English
  • Français

The effect of Citalopram in panic disorder

Published online by Cambridge University Press:  03 January 2018

A. G. Wade ,
U. Lepola ,
H. J. Koponen ,
V. Pedersen  and
T. Pedersen
A. G. Wade
Affiliation:
Clydebank Health Centre, Dunbartonshire, Scotland
U. Lepola
Affiliation:
Kuopion Psykiatripalvelu Oy, Kuopio, Finland
H. J. Koponen
Affiliation:
Moisio Hospital, Mikkeli, Finland
V. Pedersen*
Affiliation:
Clinical Research Department, Copenhagen-Valby, Denmark
T. Pedersen
Affiliation:
Clinical Research Department, Copenhagen-Valby, Denmark
*
V. Pedersen, H. Lundbeck A/S, Clinical Research Department, Ottiliavej 9, DK-2500 Copenhagen-Valby, Denmark
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Citalopram is a serotonin reuptake inhibitor which has been demonstrated to be highly selective and with a superior tolerability profile to the classical tricyclic antidepressants. This study was designed to test whether there was any difference in eff icacy in the management of panic disorder (PD) between Citalopram and placebo.

Method

This was a double-blind, placebo and clomipramine controlled, parallel group eight-week study. A total of 475 patients with PD, with or without agoraphobia, were randomised to treatment with either placebo, clomipramine 60 or 90 mg/day, or Citalopram 10 or 15 mg/day, 20 or 30 mg/day, or 40 or 60 mg/day. Doses were increased over the first three weeks, stabilised during the fourth week and fixed between weeks five and eight.

Results

Treatment with Citalopram at 20 or 30 mg, 40 or 60 mg and clomipramine were significantly superior to placebo, judged by the number of patients free of panic attacks in the week prior to the final assessment. All rating scales examined suggested that Citalopram 20 or 30 mg was more effective than Citalopram 40 or 60 mg.

Conclusion

The most advantageous benefit/risk ratio for the treatment of PD was associated with citalopram 20 or 30 mg/day.

Type
Papers
Information
The British Journal of Psychiatry , Volume 170 , Issue 6 , June 1997 , pp. 549 - 553
Copyright
Copyright © 1997 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alexander, P. E. & Alexander, D. D. (1986) Alprazolam treatment for panic disorders. Journal of Clinical Psychiatry, 47, 301–304.Google Scholar
American Psychiatric Association (1987) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised) (DSM - III - R). Washington, DC: APA.Google Scholar
American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (4th edn) (DSM-IV). Wàshington, DC: APA Google Scholar
Andersch, S., Rosenberg, N. K., Kullingsjö, H., et al (1991) Efficacy and safety of alprazolam, Imipramine and placebo in treating panic disorder: a Scandinavian multicentre study. Acta Psychiatrica Scondinavico, suppl. 365, 18–27.Google Scholar
Ballanger, J. C., Burrows, G. D., Du Pont, R. L., et al (1988) Alprazolam in panic disorder and agoraphobia: results from a multicerrter trial. Archives of General Psychiatry, 25, 413–422.Google Scholar
Cross-National Collaborative Study (1992) Drug treatment of panic disorder. British Journal of Psychiatry, 160, 191–202.Google Scholar
Hamilton, M. (1959) The assessment of anxiety by rating. British Journal of Medical Psychology, 32, 50–55.CrossRefGoogle ScholarPubMed
Hoehn-Sark, R., McLeod, D. R. & Hipsley, P. A. (1993) Effect of fluvoxamine on panic disorder. Journal of Clinical Psychopharmocology, 13, 321–326.Google Scholar
Humble, M. & Wistedt, B. (1992) Serotonin, panic disorder and agoraphobia: short term and long term efficacy of Citalopram in panic disorders. Internavond Clinical Psychopharmacology, suppl. 6, 21–39.Google Scholar
Hyttel, J., Arnt, J. & Sanchez, C. (1995) The pharmacology of Citalopram. Reviews in Contemporary Pharmacotherapy, 6, 271–285.Google Scholar
Kahn, R. S. & van Praag, H. M. (1992) Panic disorder: a biological perspective. European Neuropsychopharmacobgy, 2, 1–20.Google Scholar
Lepola, U., Leinonen, E., Turtonen, J., et al (1994) The effect of Citalopram in panic disorder and agoraphobia: a pilot study. Nordic Journal of Psychiatry, 48, 13–17.Google Scholar
Maier, W. & Philipp, M. (1985) Comparative analysis of observer depression scales. Acta Psychiatrica Scandinavica, 72, 239–245.Google Scholar
Maier, W. & Philipp, M., Buller, R., Philipp, M., et al (1988) The Hamilton Anxiety Scale: reliability, validity, and sensitivity to change in anxiety and depressive disorders. Journal of Affective Disorders, 14, 61–68.CrossRefGoogle ScholarPubMed
Maier, W. & Philipp, M., Buller, R., Philipp, M., Roth, S. M., Argyl, N., et al (1991) Avoidance behaviour: a predictor on the efficacy of pharmacotherapy in panic disorder. European Archives of Psychiatry and Clinical Neuro-sciences, 241, 151–158.Google Scholar
Marks, I. M., Swinson, R. P., Basoglu, M., et al (1993) Alprazolam and exposure alone and combined in panic disorder with agoraphobia. British Journal of Psychiatry 182, 776–787.Google Scholar
Modigh, K., Westberg, P. & Erikkson, E. (1992) Superiority of clomipramine over Imipramine in the treatment of panic disorder: a placebo controlled trial. Journal of Clinical Psychopharmacology: 12, 251–261.Google Scholar
Montgomery, S. A. & Åsberg, M. (1979) A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382–389.Google Scholar
Montgomery, S. A. & Åsberg, M. & Johnson, F. N. (1995) Citalopram in the treatment of depression. Reviews in Contemporary Pharmacotherapy, 6, 297–306.Google Scholar
Nutt, D. (1995) The role of SSRIs in anxiety disorders. European Neuropsychopharmacobgy 5, 260–261.Google Scholar
Oehrberg, S., Christiansen, P. E., Behnke, K., et al (1995) Paroxetine in the treatment of panic disorder: a randomised, double-blind, placebo controlled study. British purnal of Psychiatry, 167, 374–379.Google Scholar
Sheehan, D. V. (1979) The Anxiety Disease. New York: Charles Scribner.Google Scholar
Snaith, R. P., Baugh, S. J., Clayden, A. D., et al (1982) The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale. British Journal of Psychiatry, 141, 518–523.Google Scholar
Spier, S., Tesar, G., Rosenbaum, J., et al (1986) Clonazepam in the treatment of panic disorder and agoraphobia. Journal of Clinical Psychiatry 47, 238–242.Google Scholar
World Health Organization (1989) WHO Adverse Reaction Terminology. Uppsala: WHO Collaborating Centre for Drug Monitoring Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.